Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DVA stock price vs DGX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DGX's multiple
Needs DGX P/E.
Implied fair value · at DVA's multiple
Needs DVA P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DAVITA INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Quest Diagnostics Inc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
WEST PHARMACEUTICAL SERVICES INC
DVA vs WST
BAXTER INTERNATIONAL INC
DVA vs BAX
MCKESSON CORP
DVA vs MCK
Cigna Group
DVA vs CI
LABCORP HOLDINGS INC.
DVA vs LH
ABBOTT LABORATORIES
DVA vs ABT
DANAHER CORP /DE/
DVA vs DHR
THERMO FISHER SCIENTIFIC INC.
DVA vs TMO
HCA Healthcare, Inc.
DVA vs HCA
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DVA can sustain its high ROIC (23.0%) and materially reduce net leverage from 6.0x toward DGX levels, then consider buying for a potential re-rating toward the DGX-implied P/E (implied $218.35, ~46% upside); otherwise, hold or avoid given the low Altman Z-Score (1.57) and margin/earnings weaknesses.
DVA is materially discounted to a DGX-based P/E implied price (DVA current $149.45 vs implied $218.35, ~46% upside). The discount is consistent across valuation multiples (P/E, P/S) though DVA sits comfortably inside its historical band.
Supporting Metrics
